Purple Biotech
PPBT
5 hedge funds and large institutions have $96K invested in Purple Biotech in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 0 closing their positions.
123% more capital invested
Capital invested by funds: $43K → $96K (+$53K)
0% more funds holding
Funds holding: 5 → 5 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$29.2K |
| 2 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
+$5.84K |
| 3 |
VF
Virtu Financial
New York
|
+$5.84K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.38K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $53K | +$29.2K | +20 | +143% |
|
|
VF
2
Virtu Financial
New York
| $16K | +$5.84K | +4 | +67% |
|
|
KWM
3
Kingsview Wealth Management
Grants Pass,
Oregon
| $13K | – | – | – |
|
|
ASN
4
Advisory Services Network
Atlanta,
Georgia
| $8K | +$5.84K | +4 | +400% |
|
|
5
UBS Group
Zurich,
Switzerland
| $6K | +$4.38K | +3 | +300% |
|
PPBT Hedge Fund Activity: Q4 2019 in Review
5 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q4 2019, worth a combined $96K — up 123% from $43K a quarter earlier.
Fund positioning in PPBT was balanced in Q4 2019: 0 funds opened new positions, 0 closed out, 4 added to existing stakes and 0 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $29.2K.
- 5 institutional investors held Purple Biotech (PPBT) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $96K of Purple Biotech stock for Q4 2019, up 123% quarter-over-quarter.
- 0 funds opened new Purple Biotech positions in Q4 2019 and 0 closed out.
- The largest Purple Biotech buyer in Q4 2019 was Morgan Stanley, an estimated $29.2K added.
Based on aggregated 13F filings for Q4 2019.